FDA grants Priority Review for plinabulin with G-CSF for the prevention of chemotherapy-induced neutropoenia

Plinabulin is an intravenous small molecule selective immunomodulating microtubule-binding agent (SIMBA). Data from the PROTECTIVE-2 Phase 3 trial supported the application, which found reduced rates of grade 4 neutropenia as compared to G-CSF alone.

Source:

Biospace Inc.